Several reports have shed light on the involvement of BTK in AML, especially in the context of FLT3-ITD mutation [32, 33, 42–44], and ARQ 531 potently inhibits BTK in the AML cell lines independent of FLT3 status (Fig. 3d). Here, BTK is linked to acute myeloid leukemia.